Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2020 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, 2020
Slide 1: Agilent Technologies Q1'20 Results Presentation
Agilent Technologies Q1'20 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth o
Slide 3: Agilent Results Q1'20
Agilent Results Q1'20 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1'20 Financial Metrics Q1'20 Highlights • Revenues: $1.36B, +2.4% y/y • Growth: Balanced gains across all regions and end core(1)(2),+5.7% reported (+3.7% M&A, -0.4% markets. Estimated impact
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Core Revenue performance reflected continued Instrumentation and Informatics for Analytical Laboratories strength in Environmental & Forensics markets and stable Chemical & Energy offset by softness in China Food and Pharma. • BioTek delivered a very st
Slide 5: Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance across Analytical Laboratory Consumables and Services both services and consumables. Balanced growth across major markets and regions. • ACG grew in the low-teens in China, leveraging Agilent’s large instrument installed base and e
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Healthy core revenue growth driven by continued Pathology, Genomics, and strong NASD, high single digit growth in the NGS Nucleic Acid Manufacturing portfolio, and mid single digit growth in Pathology related businesses. • New Frederick, Colorado NASD manufactu
Slide 7: Growth in a $52B Market – Q1'20 Results by End Market
Growth in a $52B Market – Q1'20 Results by End Market Balanced Gains across Markets led by Strength in Services and Consumables Analytical Laboratory End Markets Q1'20 revenues: +2% y/y on core(2) basis Pharma & Biotech: Up 3% with strength in Bio-Pharma, Chemical Services, Chemistries and Consu
Slide 8: Q2'20 and FY20 Guidance and Forward-looking Considerations
Q2’20 and FY20 Guidance and Forward-looking Considerations Based on January 31, 2020 Exchange Rates Q2’20 Guidance (1) FY20 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,280 $1,320 Net Revenue ($M) $5,500 $5,550 Y/Y Core Revenue Growth (2) 1.0% 4.0% Y/Y Core Revenue Growth (2) 4